Journal of Korean Physical Therapy Science (대한물리치료과학회지)

Korean Physical Therapy Science (대한물리치료과학회)
권호 표지
DOI QR코드

DOI QR Code

The Cytokine-mediated Link Between Depression and Cachexia in Cancer Patients

암환자의 우울증과 카켁시아 간 시토카인 매개 연결

  • 임우택 (우송대학교 물리치료학과)
  • Received : 2019.10.29
  • Accepted : 2019.12.09
  • Published : 2019.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Despite the advances in medical technology, there are limited therapeutic interventions for cancer. Currently, the main goal of treatment is to remove a tumor completely. However, recent studies have shown that mortality is highly influenced by symptoms such as depression and cachexia, not solely by cancer itself. Depression is caused by psychological stress, and cachexia involves extreme weight loss with skeletal muscle atrophy, which are widely observed in patients with cancer. Although those two appear completely different from each other, they have a common etiology: cytokines. The production of cytokines can lead to depression and cachexia, and it contributes greatly to the increase in mortality rate. A better understanding of depression and cachexia in patients with cancer will help establish efficient treatment strategies.

Keywords

References

  1. Aass N, Fossa SD, Dahl AA, et al. Prevalence of anxiety and depression in cancer patients seen at the Norwegian Radium Hospital. Eur J Cancer. 1997;33(10):1597-1604. https://doi.org/10.1016/S0959-8049(97)00054-3
  2. Arai H, Ouchi Y, Toba K, et al. Japan as the front-runner of super-aged societies: Perspectives from medicine and medical care in Japan. Geriatr Gerontol Int. 2015;15(6):673-687. https://doi.org/10.1111/ggi.12450
  3. Argiles JM, Busquets S, Lopez-Soriano FJ. Anti-inflammatory therapies in cancer cachexia. Eur J Pharmacol. 2011;668 Suppl 1:S81-86. https://doi.org/10.1016/j.ejphar.2011.07.007
  4. Argiles JM, Lopez-Soriano FJ. The role of cytokines in cancer cachexia. Med Res Rev. 1999;19(3):223-248. https://doi.org/10.1002/(SICI)1098-1128(199905)19:3<223::AID-MED3>3.0.CO;2-N
  5. Baltgalvis KA, Berger FG, Pena MMO, et al. Interleukin-6 and cachexia in ApcMin/+ mice. Am J Physiol Regul Integr Comp Physiol. 2008;294(2):R393-401. https://doi.org/10.1152/ajpregu.00716.2007
  6. Berard RM, Boermeester F, Viljoen G. Depressive disorders in an out-patient oncology setting: prevalence, assessment, and management. Psychooncology. 1998;7(2):112-120. https://doi.org/10.1002/(SICI)1099-1611(199803/04)7:2<112::AID-PON300>3.0.CO;2-W
  7. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007;81(1):1-5. https://doi.org/10.1189/jlb.0306164
  8. Black PH. Central nervous system-immune system interactions: psychoneuroendocrinology of stress and its immune consequences. Antimicrob Agents Chemother. 1994;38(1):1-6. https://doi.org/10.1128/AAC.38.1.1
  9. Bodurka-Bevers D, Basen-Engquist K, Carmack CL, et al. Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol. 2000;78(3 Pt 1):302-308. https://doi.org/10.1006/gyno.2000.5908
  10. Bossola M, Muscaritoli M, Costelli P, et al. Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am J Physiol Regul Integr Comp Physiol. 2001;280(5):R1518-1523. https://doi.org/10.1152/ajpregu.2001.280.5.R1518
  11. Bruera E, Neumann CM, Pituskin E, et al. Thalidomide in patients with cachexia due to terminal cancer: preliminary report. Ann Oncol. 1999;10(7):857-859. https://doi.org/10.1023/A:1008329821941
  12. Buccheri G. Depressive reactions to lung cancer are common and often followed by a poor outcome. Eur Respir J. 1998;11(1):173-178. https://doi.org/10.1183/09031936.98.11010173
  13. Busquets S, Aranda X, Ribas-Carbo M, et al. Tumour necrosis factor-alpha uncouples respiration in isolated rat mitochondria. Cytokine. 2003;22(1-2):1-4. https://doi.org/10.1016/S1043-4666(03)00098-X
  14. Caan BJ, Meyerhardt JA, Kroenke CH, et al. Explaining the Obesity Paradox: The Association between Body Composition and Colorectal Cancer Survival (C-SCANS Study). Cancer Epidemiol Biomarkers Prev. 2017;26(7):1008-1015. https://doi.org/10.1158/1055-9965.EPI-17-0200
  15. Caan BJ, Cespedes Feliciano EM, Prado CM, et al. Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer. JAMA Oncol. 2018;4(6):798-804. https://doi.org/10.1001/jamaoncol.2018.0137
  16. Carroll BT, Kathol RG, Noyes R, et al. Screening for depression and anxiety in cancer patients using the Hospital Anxiety and Depression Scale. Gen Hosp Psychiatry. 1993;15(2):69-74. https://doi.org/10.1016/0163-8343(93)90099-A
  17. Chen ML, Chang HK, Yeh CH. Anxiety and depression in Taiwanese cancer patients with and without pain. J Adv Nurs. 2000;32(4):944-951. https://doi.org/10.1046/j.1365-2648.2000.t01-1-01560.x
  18. Chochinov HM, Wilson KG, Enns M, et al. 'Are you depressed?' Screening for depression in the terminally ill. Am J Psychiatry. 1997;154(5):674-676. https://doi.org/10.1176/ajp.154.5.674
  19. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332(20):1351-1362. https://doi.org/10.1056/NEJM199505183322008
  20. Ciaramella A, Poli P. Assessment of depression among cancer patients: the role of pain, cancer type and treatment. Psychooncology. 2001;10(2):156-165. https://doi.org/10.1002/pon.505
  21. Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov. 2015;14(1):58-74. https://doi.org/10.1038/nrd4467
  22. Colon EA, Callies AL, Popkin MK, et al. Depressed mood and other variables related to bone marrow transplantation survival in acute leukemia. Psychosomatics. 1991;32(4):420-425. https://doi.org/10.1016/S0033-3182(91)72045-8
  23. Costelli P, Carbo N, Tessitore L, et al. Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. J Clin Invest. 1993;92(6):2783-2789. https://doi.org/10.1172/JCI116897
  24. Cwikel JG, Behar LC, Zabora J. Psychosocial factors that affect the survival of adult cancer patients: A review of research. Journal of psychosocial oncology. 1997;15(3-4):1-34. https://doi.org/10.1300/J077v15n03_01
  25. Dalton SO, Schuz J, Engholm G, et al. Social inequality in incidence of and survival from cancer in a population-based study in Denmark, 1994-2003: Summary of findings. Eur J Cancer. 2008;44(14):2074-2085. https://doi.org/10.1016/j.ejca.2008.06.018
  26. De Leeuw JR, De Graeff A, Ros WJ, et al. Negative and positive influences of social support on depression in patients with head and neck cancer: a prospective study. Psychooncology. 2000;9(1):20-28. https://doi.org/10.1002/(SICI)1099-1611(200001/02)9:1<20::AID-PON425>3.0.CO;2-Y
  27. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160(14):2101-2107. https://doi.org/10.1001/archinte.160.14.2101
  28. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59(12):1116-1127. https://doi.org/10.1016/j.biopsych.2006.02.013
  29. Fearon KCH, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012;16(2):153-166. https://doi.org/10.1016/j.cmet.2012.06.011
  30. Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. 2013;10(2):90-99. https://doi.org/10.1038/nrclinonc.2012.209
  31. Flynn MG, McFarlin BK. Toll-like receptor 4: link to the anti-inflammatory effects of exercise? Exerc Sport Sci Rev. 2006;34(4):176-181. https://doi.org/10.1249/01.jes.0000240027.22749.14
  32. Fong Y, Moldawer LL, Marano M, et al. Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. Am J Physiol. 1989;256(3 Pt 2):R659-665.
  33. Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: implications for health. Nat Rev Immunol. 2005;5(3):243-251. https://doi.org/10.1038/nri1571
  34. Goldberg JA, Scott RN, Davidson PM, et al. Psychological morbidity in the first year after breast surgery. Eur J Surg Oncol. 1992;18(4):327-331.
  35. Grassi L, Rosti G, Albieri G, et al. Depression and abnormal illness behavior in cancer patients. Gen Hosp Psychiatry. 1989;11(6):404-411. https://doi.org/10.1016/0163-8343(89)90135-7
  36. Holsboer F, Ising M. Central CRH system in depression and anxiety--evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol. 2008;583(2-3):350-357. https://doi.org/10.1016/j.ejphar.2007.12.032
  37. Hopwood P, Stephens RJ. Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol. 2000;18(4):893-903. https://doi.org/10.1200/JCO.2000.18.4.893
  38. Irwin MR, Miller AH. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun. 2007;21(4):374-383. https://doi.org/10.1016/j.bbi.2007.01.010
  39. Kathol RG, Mutgi A, Williams J, et al. Diagnosis of major depression in cancer patients according to four sets of criteria. Am J Psychiatry. 1990;147(8):1021-1024. https://doi.org/10.1176/ajp.147.8.1021
  40. Kelsen DP, Portenoy RK, Thaler HT, et al. Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol. 1995;13(3):748-755. https://doi.org/10.1200/JCO.1995.13.3.748
  41. Kenis G, Maes M. Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol. 2002;5(4):401-412. https://doi.org/10.1017/S1461145702003164
  42. Kiecolt-Glaser JK, Glaser R. Depression and immune function: central pathways to morbidity and mortality. J Psychosom Res. 2002;53(4):873-876. https://doi.org/10.1016/S0022-3999(02)00309-4
  43. Kim YK, Maes M. The role of the cytokine network in psychological stress. Acta Neuropsychiatr. 2003;15(3):148-155. https://doi.org/10.1034/j.1601-5215.2003.00026.x
  44. Kissane DW, Clarke DM, Ikin J, et al. Psychological morbidity and quality of life in Australian women with early-stage breast cancer: a cross-sectional survey. Med J Aust. 1998;169(4):192-196. https://doi.org/10.5694/j.1326-5377.1998.tb140220.x
  45. Klausner JD, Makonkawkeyoon S, Akarasewi P, et al. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11(3):247-257. https://doi.org/10.1097/00042560-199603010-00005
  46. Kuchler T, Henne-Bruns D, Rappat S, et al. Impact of psychotherapeutic support on gastrointestinal cancer patients undergoing surgery: survival results of a trial. Hepatogastroenterology. 1999;46(25):322-335.
  47. Kugaya A, Akechi T, Okuyama T, et al. Prevalence, predictive factors, and screening for psychologic distress in patients with newly diagnosed head and neck cancer. Cancer. 2000;88(12):2817-2823. https://doi.org/10.1002/1097-0142(20000615)88:12<2817::AID-CNCR22>3.0.CO;2-N
  48. Kuroda K, Nakashima J, Kanao K, et al. Interleukin 6 is associated with cachexia in patients with prostate cancer. Urology. 2007;69(1):113-117. https://doi.org/10.1016/j.urology.2006.09.039
  49. Lansky SB, List MA, Herrmann CA, et al. Absence of major depressive disorder in female cancer patients. J Clin Oncol. 1985;3(11):1553-1560. https://doi.org/10.1200/JCO.1985.3.11.1553
  50. Lasry JC, Margolese RG, Poisson R, et al. Depression and body image following mastectomy and lumpectomy. J Chronic Dis. 1987;40(6):529-534. https://doi.org/10.1016/0021-9681(87)90010-5
  51. Laviano A, Meguid MM, Inui A, et al. Therapy insight: Cancer anorexia-cachexia syndrome--when all you can eat is yourself. Nat Clin Pract Oncol. 2005;2(3):158-165. https://doi.org/10.1038/ncponc0112
  52. Linden W, Vodermaier A, Mackenzie R, et al. Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. J Affect Disord. 2012;141(2-3):343-351. https://doi.org/10.1016/j.jad.2012.03.025
  53. Little JP, Phillips SM. Resistance exercise and nutrition to counteract muscle wasting. Appl Physiol Nutr Metab. 2009;34(5):817-828. https://doi.org/10.1139/H09-093
  54. Lundholm K, Gelin J, Hyltander A, et al. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res. 1994;54(21):5602-5606.
  55. Mantovani G, Maccio A, Mura L, et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med. 2000;78(10):554-561. https://doi.org/10.1007/s001090000137
  56. Massie, M. J., and M. K. Popkin. "Depressive disorders. en Psycho-oncology. Editor: Jimmie C. Holland.";1998.p.518-540.
  57. McCorkle R, Strumpf NE, Nuamah IF, et al. A specialized home care intervention improves survival among older post-surgical cancer patients. J Am Geriatr Soc. 2000;48(12):1707-1713. https://doi.org/10.1111/j.1532-5415.2000.tb03886.x
  58. McMillan DC, Leen E, Smith J, et al. Effect of extended ibuprofen administration on the acute phase protein response in colorectal cancer patients. Eur J Surg Oncol. 1995;21(5):531-534. https://doi.org/10.1016/S0748-7983(95)97157-2
  59. Mishel MH, Hostetter T, King B, et al. Predictors of psychosocial adjustment in patients newly diagnosed with gynecological cancer. Cancer Nurs. 1984;7(4):291-299.
  60. Monk JP, Phillips G, Waite R, et al. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol. 2006;24(12):1852-1859. https://doi.org/10.1200/JCO.2005.04.2838
  61. Musselman DL, Miller AH, Porter MR, et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry. 2001;158(8):1252-1257. https://doi.org/10.1176/appi.ajp.158.8.1252
  62. Newport DJ, Nemeroff CB. Assessment and treatment of depression in the cancer patient. J Psychosom Res. 1998;45(3):215-237. https://doi.org/10.1016/S0022-3999(98)00011-7
  63. Pace TWW, Hu F, Miller AH. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun. 2007;21(1):9-19. https://doi.org/10.1016/j.bbi.2006.08.009
  64. Pascoe S, Edelman S, Kidman A. Prevalence of psychological distress and use of support services by cancer patients at Sydney hospitals. Aust N Z J Psychiatry. 2000;34(5):785-791. https://doi.org/10.1080/j.1440-1614.2000.00817.x
  65. Pinder KL, Ramirez AJ, Black ME, et al. Psychiatric disorder in patients with advanced breast cancer: prevalence and associated factors. Eur J Cancer. 1993;29A(4):524-527.
  66. Pinquart M, Duberstein PR. Depression and cancer mortality: a meta-analysis. Psychol Med. 2010; 40(11):1797-1810. https://doi.org/10.1017/S0033291709992285
  67. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27(1):24-31. https://doi.org/10.1016/j.it.2005.11.006
  68. Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry. 2003;160(9):1554-1565. https://doi.org/10.1176/appi.ajp.160.9.1554
  69. Reid J, Mills M, Cantwell M, et al. Thalidomide for managing cancer cachexia. Cochrane Database Syst Rev. 2012;(4):CD008664.
  70. Richardson JL, Shelton DR, Krailo M, et al. The effect of compliance with treatment on survival among patients with hematologic malignancies. J Clin Oncol. 1990;8(2):356-364. https://doi.org/10.1200/JCO.1990.8.2.356
  71. Schlesinger S, Siegert S, Koch M, et al. Postdiagnosis body mass index and risk of mortality in colorectal cancer survivors: a prospective study and meta-analysis. Cancer Causes Control. 2014;25(10):1407-1418. https://doi.org/10.1007/s10552-014-0435-x
  72. Shachar SS, Deal AM, Weinberg M, et al. Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane Based Chemotherapy. Clin Cancer Res. 2017;23(3):658-665. https://doi.org/10.1158/1078-0432.CCR-16-0940
  73. Skarstein J, Aass N, Fossa SD, et al. Anxiety and depression in cancer patients: relation between the Hospital Anxiety and Depression Scale and the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire. J Psychosom Res. 2000;49(1):27-34. https://doi.org/10.1016/S0022-3999(00)00080-5
  74. Soygur H, Palaoglu O, Akarsu ES, et al. Interleukin-6 levels and HPA axis activation in breast cancer patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(6):1242-1247. https://doi.org/10.1016/j.pnpbp.2007.05.001
  75. Spiegel D, Bloom JR, Yalom I. Group support for patients with metastatic cancer. A randomized outcome study. Arch Gen Psychiatry. 1981;38(5):527-533. https://doi.org/10.1001/archpsyc.1980.01780300039004
  76. Spiegel D, Giese-Davis J. Depression and cancer: mechanisms and disease progression. Biol Psychiatry. 2003;54(3):269-282. https://doi.org/10.1016/S0006-3223(03)00566-3
  77. Stefanek ME, Derogatis LP, Shaw A. Psychological distress among oncology outpatients. Prevalence and severity as measured with the Brief Symptom Inventory. Psychosomatics. 1987;28(10):530-532, 537-539. https://doi.org/10.1016/S0033-3182(87)72467-0
  78. Thomas DR. Distinguishing starvation from cachexia. Clin Geriatr Med. 2002;18(4):883-891. https://doi.org/10.1016/S0749-0690(02)00032-0
  79. Tisdale MJ. Biology of cachexia. J Natl Cancer Inst. 1997;89(23):1763-1773. https://doi.org/10.1093/jnci/89.23.1763
  80. Torelli GF, Meguid MM, Moldawer LL, et al. Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats. Am J Physiol. 1999;277(3):R850-855.
  81. Wang H, Hai S, Liu Y, et al. Skeletal Muscle Mass as a Mortality Predictor among Nonagenarians and Centenarians: A Prospective Cohort Study. Sci Rep. 2019;9(1):2420. https://doi.org/10.1038/s41598-019-38893-0
  82. Wulsin LR, Vaillant GE, Wells VE. A systematic review of the mortality of depression. Psychosom Med. 1999;61(1):6-17. https://doi.org/10.1097/00006842-199901000-00003
  83. Zabora J, BrintzenhofeSzoc K, Curbow B, et al. The prevalence of psychological distress by cancer site. Psychooncology. 2001;10(1):19-28. https://doi.org/10.1002/1099-1611(200101/02)10:1<19::AID-PON501>3.0.CO;2-6
  84. Zaki MH, Nemeth JA, Trikha M. CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int J Cancer. 2004;111(4):592-595. https://doi.org/10.1002/ijc.20270
  85. Zhu CB, Carneiro AM, Dostmann WR, et al. p38 MAPK activation elevates serotonin transport activity via a trafficking-independent, protein phosphatase 2A-dependent process. J Biol Chem. 2005; 280(16):15649-15658. https://doi.org/10.1074/jbc.M410858200